TIRAT HACARMEL, Israel, Sept. 26 /PRNewswire/ -- Ultra Cure Ltd. develops
therapeutic ultrasound methods and devices, for cosmetic and medical
applications, based on its unique proprietary technology, which incorporates
advantages of ultrasound (mechanical waves) over laser (electro-magnetic wave)
and other treatment techniques.
R&D is based on market needs, where time to market plays an important
role. Currently, the company emphasizes superficial-tissue treatments,
including skin resurfacing, in particular peeling, and hair removal (annual
global-market demands of $3.5 and $4.5 billion respectively). Mid-term R&D
goals are focused on cosmetic disorders, as noticeable vascular disorders.
Superficial skin disorders will quantitatively increase with time, subsequent
to significant deterioration of atmospheric conditions combined with aging
problems due to extended life expectancies. Concurrently, an increased
standard of living, leisure time and health-care awareness, will motivate
individuals to spend considerable money in this direction.
The company's long-term R&D:
-- Transdermal delivery of compounds
-- Treatment of pathological or undesired, deeply located tissues by
non-invasive manipulations.
Estimated market size include more than one million procedures of skin
resurfacing which have been performed in the U.S. during 1997 -- annual global
market of over $3 billion. Estimated global demand for permanent epilation
exceeded $4 billion in 1997. Both applications have an expected annual growth
rate of 5-10%. Full Market potential include salons (550,000 sites
worldwide), clinics (40,000) and consumers.
Assuming 10% penetration after 5 years of just the top tier salons, the
potential is $220 million.
Ultra Cure's platform technology is comprised of twelve patent
applications --
-- Hair removal
-- Skin peeling
-- Transdermal delivery
-- Blood vessel elimination
The final treatment devise will be both portable and computerized, to be
used for peeling and hair removal (the company's leading short term products)
by dermatologists, plastic surgeons, and aestheticians and aestheticians in
medical centers, private clinics or cosmetic institutes. Medical devices will
be designed for use by physicians. Transdermal delivery devices will be
designated for either medical center applications or home personal use.
The company was founded in 1997 and has developed several procedures,
concepts of devices, established its intellectual property and completed its
market study. Concomitantly, biological feasibility of procedures was
approved. Ultra Cure's personnel include scientists of four different
disciplines: Physics, Biology, Chemistry and Medical Engineering, and a wide
management board.
SOURCE Ultra Cure Ltd.
 back to top
Related links:
http://ihshealth.com
Company News On-Call:
http://www.prnewswire.com/comp/152896.html or fax,
800-758-5804, ext. 152896
CONTACT:
Iris Arbel of Ultra Cure Ltd.,
011-972-4-858-14-14, or iris@ultra-cure.com
|
